Completed PHASE3 INTERVENTIONAL NCT00032175

Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer

Sponsor: Cancer Research UK

Conditions Pancreatic Cancer

Interventions capecitabine gemcitabine hydrochloride

Updated 6 times since 2017 Last updated: Jun 25, 2013 Started: Apr 30, 2002 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pancreatic Cancer and is currently completed. Cancer Research UK leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Research UK

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Bath, United Kingdom , Bournemouth, United Kingdom , Bristol, United Kingdom , Cambridge, United Kingdom , Derby, United Kingdom , Exeter, United Kingdom , Ipswich, United Kingdom , Kings Lynn, United Kingdom , Leeds, United Kingdom and 19 more locations